Results 71 to 80 of about 14,491 (226)
Pathology oncology research : PORBackground Alectinib is effective in extending the survival of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and generally has manageable side effects.
Zijian Qiu, Fei Ke, Xiaoping Zhu
semanticscholar +1 more source
Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice. [PDF]
, 2016 Exosomes are nano-sized vesicles of endolysosomal origin, released by several cytotypes in physiological and pathological conditions. Tumor derived exosomes, interacting with other cells of the tumor microenvironment, modulate tumor progression ...
Antonio Araújo
core +5 more sources
MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. [PDF]
, 2019 Lung cancer remains the most lethal cancer among men and women in the United States and worldwide. The majority of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Developing new therapeutics on the basis of better understanding of
Petrek, Hannah, Yu, Ai-Ming
core +1 more source
Cancer Science, EarlyView.The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori +12 more
wiley +1 more source
Clinical Case Reports, 2017 Key Clinical Message Alectinib shows remarkable efficacy against anaplastic lymphoma kinase (ALK)‐positive nonsmall cell lung cancer (NSCLC), with minimal adverse effects. Therefore, alectinib may provide a survival benefit to ALK‐positive NSCLC patients
Osamu Kanai +4 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 713-720, March 2026.Traditional drug‐food interaction studies of oral anticancer agents have a high patient burden. A patient‐friendly alternative approach to studying food effects could be the use of stable isotopically labeled microtracers. A prospective, single‐center, open‐label, crossover, food effect study with the microtracer 2H6‐alectinib was conducted in patients
Ma Ida Mohmaed Ali +9 more
wiley +1 more source
Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients [PDF]
, 2017 Background: The identification of anaplastic lymphoma kinase (ALK) rearrangements is found in approximately 5% of non-small-cell lung cancers (NSCLCs).
Calvo, Virginia +13 more
core +3 more sources
A Giant Thoracic ALK‐Rearranged Mesenchymal Neoplasm in a Child
Cancer Reports, Volume 9, Issue 2, February 2026.ABSTRACT Background Mesenchymal neoplasms characterized by ALK fusions mainly include inflammatory myofibroblastic tumors (IMTs) and epithelioid fibrous histiocytomas (EFHs). More recently, ALK‐rearranged mesenchymal tumors that are not IMTs or EFHs, characterized by S100 and CD34 coexpression, have been reported in a few small series and isolated case
Sheng Gao +9 more
wiley +1 more source
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. [PDF]
, 2018 Non-small cell lung cancer (NSCLC) is one of the most prevalent cancers and is responsible for a large proportion of all cancer-related deaths. Current treatment options are inadequate, reflecting a substantial unmet clinical need.
Kerr, K.M., Peters, S., Stahel, R.
core +2 more sources
The emerging therapeutic landscape of alk inhibitors in non-small cell lung cancer [PDF]
, 2020 The treatment of metastatic non-small cell lung cancer (NSCLC) has undergone a paradigm shift over the last decade. Better molecular characterization of the disease has led to the rapid improvement of personalized medicine and the prompt delivery of ...
Bazan V. +5 more
core +1 more source